menu
    • menu
    [{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"n.c.a Lutetium-177","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ SHINE Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ SHINE Technologies"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Pharma15","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ Radiopharm Theranostics"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"TerThera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"RAD602","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Radiopharm Theranostics \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ Radiopharm Theranostics"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"68Ga-Trivehexin","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Not Applicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"TerThera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"RAD 402","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ Radiopharm Theranostics"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"RAD204","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Not Applicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"[68Ga]-Trivehexin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Radiopharm Theranostics","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ Lantheus Holding","highestDevelopmentStatusID":"12","companyTruncated":"Radiopharm Theranostics \/ Lantheus Holding"}]

    Find Clinical Drug Pipeline Developments & Deals by Radiopharm Theranostics

    Menu

    Radiopharm Theranostics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : [68Ga]-Trivehexin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Lantheus Holding

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Radiopharm Receives Strategic Investment for up to A$18 million

                            Details : The company will use the net proceeds of Lantheus’ investment for drug advancement RAD301 ([68Ga]-Trivehexin), which is being evaluated for treating pancreatic neoplasms.

                            Brand Name : RAD301

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 19, 2024

                            Lead Product(s) : [68Ga]-Trivehexin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Lantheus Holding

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAD204

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RAD Receives Approval for Phase 1 Therapeutic Study of PDL1-nanobody in Non-Small Cell Lung Cancer

                            Details : RAD204, which targets PDL1-positive NSCLC, which used technology underpinning the trial is Radiopharm’s proprietary nanobody from its NanoMab platform.

                            Brand Name : RAD204

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 09, 2023

                            Lead Product(s) : RAD204

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAD 402,Terbium-161

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : TerThera

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Radiopharm Theranostics Expands Supply Agreement with TerThera for Terbium-161 Isotope Use in Prostate Cancer

                            Details : Under the agreement, TerThera will supply Radiopharm with Terbium-161 and Tb-161 isotope will be linked to a proprietary mAb to form RAD 402, a radiotherapeutic that is being developed by Radiopharm to target KLK3 expression in patients with advanced pro...

                            Brand Name : RAD 402

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 24, 2023

                            Lead Product(s) : RAD 402,Terbium-161

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : TerThera

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68Ga-Trivehexin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer

                            Details : RAD301 (68Ga-Trivehexin) is a proprietary peptide-based molecule that targets avf6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with decreased survival in several carcinomas.

                            Brand Name : RAD301

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 09, 2023

                            Lead Product(s) : 68Ga-Trivehexin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAD602

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : TerThera

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope

                            Details : The agreement aims to supply Tb-161 for RAD 602, a radiotherapeutic that is being developed by Radiopharm to target protein tyrosine phosphatase mu (PTPmu or PTPμ) for treatment of brain cancers.

                            Brand Name : RAD602

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 17, 2023

                            Lead Product(s) : RAD602

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : TerThera

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Pharma15

                            Deal Size : $4.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceutical...

                            Details : Pharma15 is developing assets which seek to overcome resistance to prostate-specific membrane antigen (PSMA) targeting cancer therapies currently available or in late-stage development.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $2.0 million

                            March 03, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Pharma15

                            Deal Size : $4.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : n.c.a Lutetium-177

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : SHINE Technologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Radiopharm Theranostics and SHINE Technologies Announce Clinical Supply Agreement for Cancer-Fighting Medical ...

                            Details : The isotope will be used by Radiopharm in the development of its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products including RAD206. Lu-177 is an important isotope utilized in multiple programs across Radiopharm’s portfolio.

                            Brand Name : RAD206

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 19, 2022

                            Lead Product(s) : n.c.a Lutetium-177

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : SHINE Technologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth